Overview
Metastatic keratinizing squamous cell carcinoma, specifically cutaneous squamous cell carcinoma (cSCC), is an advanced form of the disease. Immunotherapy, particularly PD-1 inhibitors, is a treatment option for this condition 1.Diagnosis
No information on diagnosis is available in the provided abstracts.Management
PD-1 inhibitors are used in the treatment of advanced cutaneous squamous cell carcinoma (cSCC) 1.
A meta-analysis of seven articles including 453 patients reported a pooled objective response rate (ORR) of 44% (95% CI: 39-49%) for PD-1 inhibitors in advanced cSCC 1.
Subgroup analysis of the odds ratio (OR) for ORR for patients by PD-L1 tumour proportion score (TPS) was performed 1.Special Populations
No information on special populations is available in the provided abstracts.Key Recommendations
PD-1 inhibitors are an immunotherapeutic option for advanced cutaneous squamous cell carcinoma (cSCC) 1. (Evidence: Moderate)
The pooled objective response rate (ORR) for PD-1 inhibitors in advanced cSCC is estimated at 44% 1. (Evidence: Moderate)
PD-L1 tumour proportion score (TPS) may be a factor in assessing response to PD-1 inhibitors 1. (Evidence: Weak)References
1 Aboul-Fettouh N, Chen L, Ma J, Patel J, Silapunt S, Migden M. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. The Australasian journal of dermatology 2022. link